Discrepancies between primary tumor and metastasis: Impact on personalized medicine;Discordances entre tumeur primitive et métastases : Quel impact sur le développement de la médecine personnalisée ?

Bulletin du Cancer

Volumn 100, Issue 6, 2013, Pages 561-568

  Vignot, Stéphane ^a,b   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Discrepancies; Metastasis; Personalized medicine; Primary tumor

Indexed keywords

BIOLOGICAL MARKER;

EVALUATION; HUMAN; METHODOLOGY; ONCOLOGY; PERSONALIZED MEDICINE; PRIMARY TUMOR; REVIEW; SOLID TUMOR;

EID: 84880233029     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2013.1767     Document Type: Article

References (40)

1. Vignot S, Besse B, André F, Spano JP, Soria JC. Discrepancies between primary tumor and metastasis : a literature review on clinically established biomarkers. Crit Rev Oncol Hematol 2012 ; 84 : 301-13.
2. Lorincz T, Toth J, Badalian G, Timar J, Szendroi M. HER-2/neu genotype of breast cancer may change in bone metastasis. Pathol Oncol Res 2006 ; 12 : 149-52.
3. Amir E, Clemons M, Purdie CA, et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer treatment reviews 2012 ; 38 : 708-14.
4. Harris GC, Denley HE, Pinder SE, et al. Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. The American journal of surgical pathology 2003 ; 27 : 11-5.
5. Bruening W, Fontanarosa J, Tipton K, Treadwell JR, Launders J, Schoelles K. Systematic review: comparative effectiveness of coreneedle and open surgical biopsy to diagnose breast lesions. Annals of internal medicine 2010 ; 152 : 238-46.
6. Lebeau A, Turzynski A, Braun S, et al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol 2010 ; 28 : 3264-70.
7. Arnould L, Roger P, Macgrogan G, et al. Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH CISH and SISH vs FISH). Mod Pathol 2012 ; 25 : 675-82.
8. Taillade L, Penault-Llorca F, Boulet T, et al. Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-smallcell lung cancer. Ann Oncol 2007 ; 18 : 1043-50.
9. Bueno de Mesquita JM, Nuyten DS, Wesseling J, van Tinteren H, Linn SC, van de Vijver MJ. The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol 2010 ; 21 : 40-7.
10. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing : biologic and methodologic considerations. J Clin Oncol 2009 ; 27 : 1323-33.
11. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Archives of pathology & laboratory medicine 2010 ; 134 : 907-22.
12. Cortot AB, Italiano A, Burel-Vandenbos F, Martel-Planche G, Hainaut P. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer 2010 ; 116 : 2682-7.
13. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010 ; 12 : R75.
14. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. British journal of cancer 2010: 1139-1143.
15. Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM, Sneige N. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. Ann Oncol 2011; Jul; 22:1547-1553.
16. Watanabe T, Kobunai T, Yamamoto Y, et al. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Diseases of the colon and rectum 2011 ; 54 : 1170-8.
17. Goranova TE, Ohue M, Shimoharu Y, Kato K. Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clinical & experimental metastasis 2011 ; 28 : 427-35.
18. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England journal of medicine 2012 ; 366 : 883-92.
19. Robert J. Biology of cancer metastasis. Bulletin du cancer 2013 ; 100 : 333-42.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011 ; 144 : 646-74.
21. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. The New England journal of medicine 2009 ; 361 : 958-67.
22. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England journal of medicine 2010 ; 363 : 1693-703.
23. Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. The New England journal of medicine 2012 ; 366 : 1090-8.
24. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012 ; 30 : 2956-62.
25. Vignot S, Frampton GM, Soria JC, et al. Next-Generation Sequencing Reveals High Concordance of Recurrent Somatic Alterations Between Primary Tumor and Metastases From Patients With Non- Small-Cell Lung Cancer. J Clin Oncol 2013.
26. Gomez-Roca CA, Lacroix L, Massard C, et al. Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. Ann Oncol 2012 ; 23 : 1301-6.
27. de Bazelaire C, Farges C, Mathieu O, et al. Blunt-tip coaxial introducer: a revisited tool for difficult CT-guided biopsy in the chest and abdomen. AJR Am J Roentgenol 2009 ; 193 : W144-8.
28. de Kerviler E, Benet C, Briere J, de Bazelaire C. Image-guided needle biopsy for diagnosis and molecular biology in lymphomas. Best Pract Res Clin Haematol 2012 ; 25 : 29-39.
29. Wu CC, MaherMM,Shepard JA. Complications of CT-guided percutaneous needle biopsy of the chest: prevention and management. AJR Am J Roentgenol 2011 ; 196 : W678-82.
30. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009 ; 6 : 339-51.
31. Pestrin M, Bessi S, Galardi F, et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast cancer research and treatment 2009 ; 118 : 523-30.
32. Sieuwerts AM, Mostert B, Bolt-de Vries J, et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 2011 ; 17 : 3600-18.
33. Ignatiadis M, Rothe F, Chaboteaux C, et al. HER2-positive circulating tumor cells in breast cancer. PloS one 2011 ; 6 : e15624.
34. Tolmachev V, Stone-Elander S, Orlova A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. The lancet oncology 2010 ; 11 : 992-1000.
35. Penault-Llorca F, Coudry RA, Hanna WM, Osamura RY, Ruschoff J, Viale G. Experts' opinion: recommendations for retesting breast cancer metastases for HER2 and hormone receptor status. Breast 2013 ; 22 : 200-2.
36. André F, Delaloge S, Soria JC. Biology-driven phase II trials: what is the optimal model for molecular selection ? J Clin Oncol 2011 ; 29 : 1236-8.
37. Sequist LV,Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011 ; 3 : 75ra26.
38. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012 ; 18 : 1472-82.
39. Suda K, Mizuuchi H, Maehara Y, Mitsudomi T. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer metastasis reviews 2012 ; 31 : 807-14.
40. Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011 ; 3 : 90ra59.